BridgeBio Oncology Therapeutics Inc (BBOT) saw downtrend of -5.40% in the recent trading with $8.94 being its most recent. The current price level -28.48% lower than the highest price of $12.50 marked by the stock while trading over the past 52-weeks, whereas it is 5.18% higher than the lowest price of $8.50 the company dropped to over past 52-weeks. The latest news story on BBOT appeared in (GlobeNewswire) under the title “BBOT to Participate in Upcoming September Investor Healthcare Conferences”.
Squeezing the time span to 30 day period shows us the stock is currently trading -28.48% below one month high and is +5.18% above of the lowest during that time. Looking into the simple moving average, BridgeBio Oncology Therapeutics Inc (BBOT)’s stock stands at a SMA-50 of $10.32 while that of 5-day is reading $9.40.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and BBOT’s SMA-200 as of now is $10.57.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent perfor mance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperfor m, the score of 3 means hold, and the score of 4 indicates underperfor m. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
BridgeBio Oncology Therapeutics Inc Earnings – What Happened With BBOT
Coming around sales and income figures on BBOT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
BBOT – BridgeBio Oncology Therapeutics Inc Stock Earnings Estimates
Company’s EPS for the last quarter was -54.23.
BridgeBio Oncology Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key infor mation of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 18.91 million. BBOT does have institutional investors; and they hold 116.23% of the stock.
Key Metrics for BBOT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors befor e start trading into a stock. In recently reported quarter, BridgeBio Oncology Therapeutics Inc has a debt to equity ratio of 0.00.
Technical Analysis of BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for BridgeBio Oncology Therapeutics Inc (BBOT), we notice that the stock’s 20-day average volume is at 157,955 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 116,482 shares. And to end, BBOT’s 100-day average volume is 79,887 shares with 50% of the long-term indicators pointing towards Sell for the stock.
